Biodesix, Inc. (BDSX) recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s Nodify CDT blood-based lung nodule test.The Nodify CDT test is a blood-based diagnostic tool designed to detect cancer-associated autoantibodies, aiding in the identification of lung nodules that may be malignant. It helps healthcare providers prioritize patients for further diagnostic evaluation, potentially redu ...